Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
David Proudman,Urvi Desai,Dumingu Aparna Gomes,Maks Khomenko,Silas Martin,Dave Nellesen,Ulrich Neumann,Henry Grabowski
DOI: https://doi.org/10.1080/13696998.2024.2405407
2024-10-04
Journal of Medical Economics
Abstract:Aims Economic studies have found that public support of basic medical research provides important long-term benefits. In response to suggestions that private pharmaceutical research and development (R&D) funding could be totally replaced by public funding, we investigate the economic implications of such a substitution in funding roles that maintain the recent pace of pharmaceutical innovation.
medicine, general & internal,health care sciences & services